REG - Imaging Biometrics - Update and IB Nimble Webinar – 27 February 2026

Imaging BiometricsAnnouncement

11/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260211:nRSK4979Sa&default-theme=true

RNS Number : 4979S  Imaging Biometrics Limited  11 February 2026

Imaging Biometrics Limited

("IBAI" or the "Company")

Company Update

IB Nimble Webinar - 27 February 2026
(https://imagingbiometrics.us20.list-manage.com/track/click?u=ee2fb759d033ff87132180f83&id=6c880a273f&e=217f6b2d96)

 

Imaging Biometrics Limited ('IBAI') comprises two subsidiary businesses,
Imaging Biometrics LLC and Kirkstall Limited. In 2018, Imaging Biometrics, LLC
('IB') was acquired by Flying Brands Limited - now Imaging Biometrics Limited
- and Kirkstall became part of the group in October last year.

In the subsequent eight years IB advanced several innovative technologies
-including StoneChecker, LSN, and IB Zero G. Though substantial technical and
developmental progress has been made over these years, it has not resulted in
a concomitant commercial and revenue reward for shareholders. After
considerable analysis we believe that this has been the consequence of
pursuing too many projects with limited resources. One further consequence has
been that we have invested less in the core legacy products that, in
retrospect, we should have.

With the current market capitalisation of approximately £1.2m, our focus will
be on how to address and correct the wide gap between market perception and
our actual and anticipated operational performance. As a first step we hereby
provide a comprehensive and concise update on our live projects:

The last major release of IB Clinic, announced last fall, has seen initial
adoption. Several existing clinical sites have upgraded to FTB Express
processing, indicating interest in faster, more automated tumor-response
metrics. Longitudinal reporting, identified as a useful quality enhancement by
the neurosurgical community, will be added to improve the utility of IB Neuro
and FTB maps. These updates further substantiate IB Clinic as the cornerstone
of the product portfolio and position it for broader clinical adoption.

The next version of IB Nimble is nearing completion and includes integrated
DICOM viewing, a feature requested by customers. This allows imaging data to
be viewed directly within IB Nimble, facilitating the process from review to
interpretation to clinical decision-making. To support this release and inform
users, we will host a webinar on February 27, where the team will demonstrate
the new capabilities and interact with customers.

QSMetric, the platform for producing FDA-cleared, patented quantitative
susceptibility maps (QSM), has attracted initial interest. The system accepts
data directly from MRI scanners and generates QSM maps using a proprietary
algorithm. It is now being prepared for distribution to trial sites.

IB Zero G is a patented piece of intellectual property with potential
long-term applications. However, advancing this technology requires
significant resources and development time that affect focus on our primary
products. In line with our strategy, IB Zero G will remain on hold until the
Company's resources allow progress without impacting core business priorities.

IB played a central role in advancing the gallium maltolate (GaM) programme
through the successful completion of its Phase 1 clinical trial; the results
of which have now been submitted for publication. As previously communicated,
the scope and scale of a Phase 2 trial would require resources beyond what IB
can provide independently. While we are proud of the significant milestones
achieved-including FDA Fast Track designation, two Rare Pediatric Disease
designations, and two Orphan Drug Designations-the long‑term development
pathway for GaM would divert focus and resources from the continued
year‑over‑year growth of IB's core portfolio. For these reasons, we will
not focus on advancing the programme at this time. We do have
commercialisation rights to the Phase 1 trial data and will remain alert for
potential commercial opportunities.

Kirkstall Limited: Driven by the growing adoption of the improved QV1200
system and the expansion of our international distribution network, sales were
£123k in 2025 compared with £67k in 2024, an increase of 84%.

In 2025 distributors were contracted in three strategically important markets:

China, South Korea and the United States, with the appointment of MB Research
Labs ("MBR").  With over 50 years of expertise in toxicology, MBR was one of
the first CROs to offer in vitro and alternative testing methodologies and
brings strong credibility and new market access.

Relevance of UK and US government policies

The UK adheres to the "3Rs" (replace, reduce, refine) principle, overseen by
the NC3Rs. In November 2025, a strategy was launched to phase out animal
testing, with £75 million funding for alternatives including organ-on-a-chip
systems-microfluidic devices mimicking human organs using real cells to test
drug effects without animals. Key timelines: end skin/eye irritation testing
by 2026, botulinum toxin potency testing on mice by 2027, and reduce
dog/primate use in pharmacokinetic studies by at least 35% by 2030.
Organ-on-a-chip is highlighted for human-relevant results in areas like
vaccine development and toxicity assessment.

US agencies like FDA, EPA, and NIH promote "new approach methodologies"
(NAMs). The FDA Modernization Act 2.0 (2022) allowed alternatives to animal
testing for drugs, enabling sponsors to use methods such as cell-based assays
and computer models rather than requiring animal studies. In April 2025, FDA
announced phasing out animal tests initially for monoclonal antibodies,
prioritising organoids and computational models to assess drug safety. EPA
targets eliminating mammalian testing by 2035. NIH funds human-based tech,
establishing a centre for organoids in 2025 to reduce animal reliance.
Organ-on-a-chip and organoid technologies are key for predicting human
responses more accurately than animal models.

Customer Highlights

Gent University (Belgium): Published research from the Faculty of Medicine and
Health Sciences has demonstrated that models of three organs can be connected
using our system to explore gut-brain barrier communication. Notably, Gent
University evaluated two competing organ-on-a-chip systems before selecting
QV1200 for their research programme.

Blood-Brain Barrier Research:

Professor Cave and his team at Nottingham Trent University are developing
next generation blood-brain barrier (BBB) organ on a chip system by combining
their advanced nanofiber tissue scaffold inserts with Kirkstall's Quasi Vivo®
platform to recreate realistic blood flow and neurovascular interactions. By
growing the three key BBB cell types (endothelial cells, pericytes and
astrocytes) inside the QV1200 system, which continuously circulates nutrients
like real blood, the team has shown that the cells form stronger,
intercellular connections and behave much more like they do in the human body.
Importantly, the new scaffolds allow the cells to grow into their natural
three-dimensional tissue structures, unlike conventional two-dimensional cell
culture models where cells sit on flat plastic membranes without flow,
limiting their physiological behavior.  The QV1200 system's flowing, dynamic
environment helps the BBB develop faster and far more effectively than older,
static methods that lack real world physiological conditions. As a result, the
platform offers a powerful, lifelike system for high throughput testing of new
neurological treatments, enabling more reliable predictions of drug delivery
and neuroprotective effects.

Professor Cave commented, "Our partnership with Kirkstall and their Quasi
Vivo® technology is enabling us to build BBB models that are closer to human
physiology than ever before. By combining dynamic flow with our nanofiber
scaffolds, we are creating a three-dimensional tissue platform that will
transform how new neurological therapies are discovered and evaluated."

Trevor Brown CEO of IBAI commented. "We recognise and share the frustration
and disappointment experienced by shareholders in recent years and are
determined to find a new modus operandi for the future. In the current year we
are projecting a small profit and importantly, expect to have sufficient
working capital without the need to approach shareholders for new funds before
this year end and hopefully beyond."

 

The Directors of the Company accept responsibility for the contents of this
announcement.

For further information, please contact:

 

  Imaging Biometrics Ltd

 Trevor Brown/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930
 AlbR Capital Limited (Broker)

 Lucy Williams

 Tel: 020 7220 9797

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDDBGDDLGBDGLG



            Copyright 2019 Regulatory News Service, all rights reserved